← Back to Investors

Wellington Partners Life Sciences

Wellington Partners is a leading European venture capital firm with a dedicated life sciences practice. The firm invests in innovative European biotechnology, medical technology, and digital health companies, with deep expertise in supporting companies from early research stages through commercialization.

Location
Munich, Germany
Founded
1998
AUM
€500M+
Investment Range
€2M - €20M
Focus
biotech-focused
Fund Stages
seed, series-a, series-b, series-c

Investment Thesis

Wellington Partners invests in European life sciences companies with breakthrough science and strong intellectual property. They focus on companies developing novel therapeutics, medical devices, and diagnostics that address significant unmet medical needs. The firm provides hands-on support and leverages their extensive industry networks to help portfolio companies succeed.

Team

Partners / Managing Directors

  • Rolf Dienst - Managing Partner
  • Regina Hodits, PhD - General Partner, Life Sciences
  • Christian Greiser, PhD - General Partner

Other Key Team Members

  • Ingmar Hörr, PhD - Venture Partner
  • Scientific Advisory Board with expertise across therapeutic areas

Focus Areas

  • Therapeutics
  • Medical Devices
  • Diagnostics
  • Digital Health
  • Oncology
  • Immunology
  • Rare Diseases

Notable Portfolio Companies

  • BioNTech - mRNA therapeutics (IPO 2019, COVID-19 vaccine developer)
  • Immunocore - T-cell receptor therapeutics (IPO 2021)
  • MorphoSys - Antibody therapeutics (acquired by Novartis 2024)
  • Definiens - AI for pathology (acquired by AstraZeneca)
  • Molecular Health - Precision medicine software

Notable Exits

  • BioNTech - IPO (2019, NASDAQ: BNTX, market cap >$30B at peak)
  • Immunocore - IPO (2021, NASDAQ: IMCR)
  • MorphoSys - IPO, then Acquired (2024, acquired by Novartis for $2.7B)
  • Definiens - Acquired (2014, acquired by AstraZeneca)
  • U3 Pharma - Acquired (acquired by Daiichi Sankyo)

Sources